Factor XI inhibition in hemodialysis patients: the safer anticoagulation?
Kidney Int
; 106(1): 21-23, 2024 Jul.
Article
in En
| MEDLINE
| ID: mdl-38906653
ABSTRACT
Chronic hemodialysis patients exhibit an excessive cardiovascular risk and a marked increase in both thromboembolism and bleeding episodes. Factor XI inhibition may provide anticoagulation, with a low risk of bleeding, and several factor XI inhibitors, including fesomersen, an antisense oligonucleotide, are under development. Recently, a phase 2 study of fesomersen showed a good safety profile in chronic hemodialysis patients and suggested that clotting rates of the arteriovenous fistula and the dialysis circuit are lower.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Factor XI
/
Renal Dialysis
/
Hemorrhage
/
Anticoagulants
Limits:
Humans
Language:
En
Journal:
Kidney Int
Year:
2024
Document type:
Article